The present invention generally deals with vascular bypass methods. More specifically, the present invention deals with systems for performing percutaneous coronary artery bypass procedures.
Coronary arteries can become partially restricted (stenotic) or completely clogged (occluded) with plaque, thrombus, or the like. This reduces the efficiency of the heart, and can ultimately lead to a heart attack. Thus, a number of different systems and methods have been developed for treating stenotic or occluded coronary arteries.
Two methods which have been developed to treat occlusions and stenosis include balloon angioplasty and pharmacological treatment. However, where the occlusion is quite hard, it can be quite difficult, if not impossible, to cross the occlusion with an angioplasty device. In addition, some coronary stenosis are to diffuse to treat effectively with balloon angioplasty. Unfortunately, such occlusions are not readily susceptible to dissolution with chemicals either. In the past, patients with these types of occlusions have been candidates for open heart surgery to bypass the restrictions.
However, open heart surgery includes a myriad of disadvantages. Open heart surgery typically includes a great deal of postoperative pain. The pain is normally encountered because conventional open heart surgery requires that the sternum be cracked open, which is quite painful. Also, open heart surgery typically involves bypassing the occluded vessel, which, in turn, involves harvesting a vein from another part of the body for use as the bypass graft. One common source for the bypass graft is the saphenous vein which is removed from the leg. Harvesting the saphenous vein requires the surgeon to cut and peel the skin back from an area of the leg which is approximately 18 inches long and which extends upward to the groin area. This can be very traumatic and painful. Further, open heart surgery requires quite a lengthy recovery period which involves an increased hospital stay, and, consequently, greater expense.
Other than the pain and more lengthy hospital stay, open heart surgery involves other disadvantages as well. For example, during open heart surgery, it is common to cool the heart to a point where it stops. The blood from the remainder of the vasculature is then pumped through a pulmonary and cardiac bypass system. Any time the heart is stopped, there is a danger of encountering difficulty in restarting the heart (which is typically accomplished by warming the heart and massaging it). Further, even if the heart is restarted, it sometimes does not return to a correct rhythm. Also, open heart surgery can require the use of a device known as a left ventricular assist device (LVAD) to supplementarily pump blood to relieve the burden on the heart. This allows the heart to heal.
A significant reason that the heart is typically stopped during open heart surgery is that, if it were not stopped, the surgeon would be working in a dynamic environment. In such an environment, the target vessels and tissue to be treated are moving. Further, a system must be employed in such an environment to stop bleeding. Clinical studies indicate that, when blood flow is stopped using clamping devices and blood flow is diverted to a cardiac bypass system, a statistically significant instance of neurological problems caused by blood clotting results. The use of mechanical clamps to stop blood flow, and the use of a mechanical bypass system, results in an approximate six percent instance of neurological problems, such as stroke, memory failure, etc.
Given the difficulties of the techniques discussed above, another approach has been developed which does not require stoppage of the heart or an open chest during execution. This approach is to perform a bypass using a minimally invasive technique by entering the upper chest cavity, through a hole between ribs under visual observation. Such a technique is often referred to as minimally invasive direct coronary artery bypass (MIDCAB) (where the heart is not stopped) or heart port (where the heart is stopped). Such a system which is used to perform a bypass is disclosed in the Sterman et al. U.S. Pat. No. 5,452,733.
A percutaneous system for bypassing a restriction in a native vessel of a mammal having an aorta includes providing a graft having a body portion with a first end, a second end and a lumen therebetween. An aperture is formed in the aorta. The graft is inserted into the aorta and the first end of the graft is connected to the aorta about the aperture in the aorta. An aperture is then formed in the native vessel distal of the restriction. The second end of the graft is connected to the native vessel about the aperture therein such that the lumen in the graft communicates with the aorta and the native vessel.
Guide catheter 28 is first placed in aorta 14. In the preferred embodiment, guide catheter 28 enters the vasculature through a femoral artery and is passed through the vasculature, through descending aorta 18 and into a region proximate ascending aorta 16. Then, a cutting or boring device 30 is inserted through guide catheter 28. In the preferred embodiment, cutting device 30 is a guidewire or catheter having a cutting edge or cutting tip disposed at the distal end 32 thereof. Cutting device 30 is advanced through guide catheter 28 and out the distal end of guide catheter 28 and brought into contact with a portion of aorta 14 where an aperture is to be formed. Cutting device 30 is used to make an incision in the wall of the aorta.
While
In one embodiment, prior to making an incision in the wall of aorta 14, if the heart is stopped in order to prevent bleeding from the aorta after the incision is made. If the heart is stopped, it is preferably stopped using a known thoracic approach.
However, in the preferred embodiment, the heart is not stopped. Rather, blood flow through the incision in aorta 14 is prevented by other means.
Prior to making the incision in the wall of aorta 14 (either before or after cutting device 30 is advanced to the wall of aorta 14) isolation device 31 is advanced through aorta 14 to the wall region of the aorta where the incision is to be made. In one preferred embodiment, isolation device 31 is advanced through guide catheter 28. In the preferred embodiment, the tubular portion 33 of isolation device 31 extends proximally through guide catheter 28 to a vacuum pump or other device suitable for drawing a vacuum therethrough. Isolation device 31 preferably includes a catheter or tubular portion 33, a portion of which is shown in
In operation, after the distal end 35 of isolation device 31 is advanced to be adjacent the wall of aorta 14, the suction or vacuum device is actuated which pulls a vacuum through catheter portion 33 of isolation device 31 causing a vacuum to be created at the distal end 35 of isolation device 31. This causes a suction to occur in the distal end of isolation device 31 which draws the distal end 35 of isolation device 31 against the wall of aorta 14. This also removes blood from the region of the wall of the aorta where the incision is to be made and precludes additional blood flow from entering that area. Thus, a clear working space is created adjacent the wall of aorta 14 such that the incision can be made without a substantial amount of blood being released from the aorta 14 through the incision.
In another preferred embodiment, a low pressure vacuum is pulled through a guide catheter which has a flared distal end and a seal on a proximal end thereof. The sealed proximal end is preferably of the type which allows devices to be inserted therethrough while substantially maintaining a low pressure vacuum seal. Thus, the guide catheter forms a substantially sealed chamber in which the work is performed. It should also be noted that any other suitable isolation device can be used to prevent blood from flowing out of aorta 14 through the incision in the wall of aorta 14.
In any case, and in one preferred embodiment, graft assembly 34 includes coupler 36 and graft section 38. Coupler 36 is preferably a biologically compatible coupling device which has an insertion portion 40 and an annular shoulder 42. In the preferred embodiment, graft section 38 is preferably either a biologically compatible, artificial graft material (such as PTFE material), or a section of a human vein, such as a saphenous vein graft. Graft section 38 preferably has a first end 44 and a second end 46 with an inner lumen defined therebetween. Upon being inserted, graft section 38 is preferably inverted, or inside out, such that the normal inner lumen wall forms the outer wall of the graft section, while the normal outer wall forms the inner lumen wall of the graft section.
After the aperture is formed in the wall of native vessel 20, end 46 of graft section 38 is connected to native vessel 20 proximate the aperture. In one preferred embodiment, end 46 is sutured to native vessel 20 using an intraluminal suturing catheter. Intraluminal suturing devices are described in greater detail in the following U.S. Pat. No. 5,080,663 entitled SEWING DEVICE; U.S. Pat. No. 5,364,389 entitled METHOD AND APPARATUS FOR SEALING AND/OR GRASPING LUMINAL TISSUE; U.S. Pat. No. 5,545,171 entitled ANASTOMOSIS CATHETER; and U.S. Pat. No. 5,591,179 entitled ANASTOMOSIS SUTURING DEVICE AND METHOD and, which are hereby incorporated by reference. In another preferred embodiment, end 46 is advanced through the aperture in native vessel 20 and is placed in the distal portion 24 of native vessel 20. This is illustrated in
In
For instance, where transmitters 52 include an inductive magnetic coil, receiver device 54 includes a magnetic sensor array to receive the signals induced in the coil. Where transmitter array 52 includes an ultrasound transmitter, receiver 54 includes an ultrasound imager so that the relative positioning of receiver device 54 and transmitter array 52 can be determined. Where transmitter 52 includes a single point light source, or an array of point light sources, receiver device 54 includes a photodiode array or an imaging fiber optic bundle which can detect the light emitted by the light sources. In addition, where transmitters 52 include an RF transmitter, receiver device 54 includes a directional antenna. In any of the above cases, or similar cases, the relative position between transmitters 52 and receiver 54 can be determined so that end 46 of graft section 38 can be properly located adjacent parent vessel 20 relative to stenosis 26.
Alternatively, of course, graft section 38, or a wire inserted therethrough can have radiopaque markers on the distal ends thereof. In addition, a radiopaque marker can be inserted within vessel 20 distal of restriction 26. In that embodiment, bi-plane fluoroscopy is used for three dimensional localization in order to bring radiopaque markers located in vessel 20 and either in graft 38 or on the distal end of graft 38 together.
Systems for stopping blood flow have included occluding balloons. Occluding balloons have a fairly low instance of emboli formation, and therefore have a fairly low instance of neurological problems which result from the formation of emboli.
In any case, a guide catheter, such as guide catheter 28, is placed in aorta 14, and a quidewire 71 is advanced through the guide catheter. A cutting probe having the tip 72 shown in
In any case, tip 72 is moved adjacent native vessel 20. Needle 74 is then again advanced over wire 71 and native vessel 20 is pierced. Wire 71 is advanced into the native vessel 20 and contrast fluid is preferably injected to verify the position of tip 72 distal of occlusion 26 in native vessel 20. Wire 71 is held in place in the native vessel 20 as shown in
A balloon catheter system, either inserted along with graft assembly 62, or after graft assembly 62 is located in the position shown in
When balloon 84 is in place, within native vessel 21 and inside stent 70, it is inflated as shown in
Intermediate balloon 86 is then inflated. This causes a distal section of stent 70 to expand, as shown in
Balloons 86 and 88 are then deflated and the core of the delivery system; including the catheter supporting balloons 86 and 88, and including wire 71, and any other portions of introducer tip 72, are removed. Such removal is facilitated by the deployment of the stents 68 and 70 which creates adequate clearance for removal of the remainder of the system. The injection of contrast medium is then used to verify that the bypass is not leaking, and the patient's heart (if it was stopped) is then restarted.
Then, as shown in
In any case, the outer diameter of tip 104 preferably includes sheath 110. Sheath 110 preferably has an inner radial surface 112 which is impermeable to fluid flow, and an outer surface 114 which is semipermeable to fluid flow. Sheath 110 preferably includes a central portion 120 between inner surface 112 and outer surface 114 which contains either a substance suitable to enhance an anastomosis at that site, or another suitable drug. Once tip 104 is suitably located in distal region 24 of native vessel 20, inflatable balloon 116, supported by a balloon catheter 118, is inserted through graft 106 and into the interior of stent 108. Balloon 116 is then inflated to deploy stent 108 radially outwardly such that the outer diameter of tip 104 expands to a sufficient extent that it approximates the inner diameter of native vessel 20 and tightly fits therein.
Upon expansion of balloon 116, which is illustrated in
It should be noted that, in one preferred embodiment, extra working space can be created in the chest cavity in order to facilitate manipulation of the various devices described herein. According to one aspect of the present invention, a needle or cutting tip catheter is used to form an incision in the aorta as described above. Then, one of a number of things is used to create additional working space. For instance, a balloon may preferably be advanced through the hole in the aorta and expanded in the interstitial spaces proximate thereto to create additional working space. Also, bioabsorable, or removable, material can optionally be injected through the aperture in the aorta to expand the area thereabout and create additional working space. These features would preferably be used in order to replace CO2 injection which is used in, for instance, laproscopic surgery.
Further, it should be noted that bifurcated stent grafts can be used in accordance with the present invention. Such grafts are described in greater detail in the patent applications incorporated herein by reference.
Thus, it can be seen that the present invention involves a system by which coronary artery bypass procedures can be executed substantially percutaneously. This serves to significantly reduce the disadvantages associated with prior treatment techniques.
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
This application is a continuation of U.S. patent application Ser. No. 09/759,996, filed Jan. 12, 2001 now U.S. Pat. No. 6,575,168; which is a continuation of U.S. patent application Ser. No. 09/391,112, filed Sep. 7, 1999, now U.S. Pat. No. 6,253,769; which is a divisional of U.S. patent application Ser. No. 08/813,038, filed Mar. 6, 1997, now U.S. Pat. No. 6,026,814. The following U.S. patent applications are hereby fully incorporated: U.S. patent application Ser. No. 08/813,040, entitled PERCUTANEOUS BYPASS WITH BRANCHING VESSEL, filed Mar. 6, 1997, now U.S. Pat. No. 6,035,856 and assigned to the same assignee as the present application; and U.S. patent application Ser. No. 08/812,879, entitled PERCUTANEOUS BYPASS BY TUNNELING THROUGH VESSEL WALL, filed Mar. 6, 1997, now U.S. Pat. No. 6,155,264 and assigned to the same assignee as the present invention.
Number | Name | Date | Kind |
---|---|---|---|
3667069 | Blackshear et al. | Jun 1972 | A |
4016884 | Kwan-Gett | Apr 1977 | A |
4165747 | Bermant | Aug 1979 | A |
4173981 | Mortensen | Nov 1979 | A |
4190909 | Ablaza | Mar 1980 | A |
4230096 | Zeff et al. | Oct 1980 | A |
4368736 | Kaster | Jan 1983 | A |
4546499 | Possis et al. | Oct 1985 | A |
4562597 | Possis et al. | Jan 1986 | A |
4566453 | Kumano et al. | Jan 1986 | A |
4601718 | Possis et al. | Jul 1986 | A |
4610661 | Possis et al. | Sep 1986 | A |
4667673 | Li | May 1987 | A |
4690684 | McGreevy et al. | Sep 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4721109 | Healey | Jan 1988 | A |
4790819 | Li et al. | Dec 1988 | A |
4803984 | Narayanan et al. | Feb 1989 | A |
4808163 | Laub | Feb 1989 | A |
4819640 | Narayanan et al. | Apr 1989 | A |
4827931 | Longmore | May 1989 | A |
4907591 | Vasconcellos et al. | Mar 1990 | A |
4911164 | Roth | Mar 1990 | A |
4995857 | Arnold | Feb 1991 | A |
5011469 | Buckberg et al. | Apr 1991 | A |
5037428 | Picha | Aug 1991 | A |
5047039 | Avant et al. | Sep 1991 | A |
5053041 | Ansari et al. | Oct 1991 | A |
5053043 | Gottesman et al. | Oct 1991 | A |
5061245 | Waldvogel | Oct 1991 | A |
5067958 | Sandhaus | Nov 1991 | A |
5080663 | Mills et al. | Jan 1992 | A |
5080664 | Jain | Jan 1992 | A |
5104402 | Melbin | Apr 1992 | A |
5122154 | Rhodes | Jun 1992 | A |
5144961 | Chen et al. | Sep 1992 | A |
5222962 | Burkhart | Jun 1993 | A |
5222963 | Brinkerhoff et al. | Jun 1993 | A |
5222971 | Willard et al. | Jun 1993 | A |
5234445 | Walker et al. | Aug 1993 | A |
5254113 | Wilk | Oct 1993 | A |
5281236 | Bagnato et al. | Jan 1994 | A |
5282810 | Allen et al. | Feb 1994 | A |
5287861 | Wilk | Feb 1994 | A |
5308320 | Safar et al. | May 1994 | A |
5314436 | Wilk | May 1994 | A |
5314472 | Fontaine | May 1994 | A |
5323789 | Berggren et al. | Jun 1994 | A |
5330486 | Wilk | Jul 1994 | A |
5364389 | Anderson | Nov 1994 | A |
5370683 | Fontaine | Dec 1994 | A |
5382257 | Lewis et al. | Jan 1995 | A |
5383854 | Safar et al. | Jan 1995 | A |
5383928 | Scott et al. | Jan 1995 | A |
5397345 | Lazarus | Mar 1995 | A |
5403333 | Kaster et al. | Apr 1995 | A |
5409019 | Wilk | Apr 1995 | A |
5425705 | Evard et al. | Jun 1995 | A |
5425739 | Jessen | Jun 1995 | A |
5429144 | Wilk | Jul 1995 | A |
5433700 | Peters | Jul 1995 | A |
5437684 | Calabrese et al. | Aug 1995 | A |
5441507 | Wilk | Aug 1995 | A |
5443497 | Venbrux | Aug 1995 | A |
5447512 | Wilson et al. | Sep 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5452733 | Sterman et al. | Sep 1995 | A |
5456714 | Owen | Oct 1995 | A |
5472404 | Volgushev | Dec 1995 | A |
5501698 | Roth et al. | Mar 1996 | A |
5522884 | Wright | Jun 1996 | A |
5527319 | Green et al. | Jun 1996 | A |
5527324 | Krantz et al. | Jun 1996 | A |
5536251 | Evard et al. | Jul 1996 | A |
5540677 | Sinofsky | Jul 1996 | A |
5540701 | Sharkey et al. | Jul 1996 | A |
5545171 | Sharkey et al. | Aug 1996 | A |
5554162 | DeLange | Sep 1996 | A |
5556414 | Turi | Sep 1996 | A |
5556428 | Shah | Sep 1996 | A |
RE35352 | Peters | Oct 1996 | E |
5562728 | Lazarus et al. | Oct 1996 | A |
5569272 | Reed et al. | Oct 1996 | A |
5569274 | Rapacki et al. | Oct 1996 | A |
5571090 | Sherts | Nov 1996 | A |
5571215 | Sterman et al. | Nov 1996 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5588949 | Taylor et al. | Dec 1996 | A |
5591179 | Edelstein | Jan 1997 | A |
5591212 | Keimel | Jan 1997 | A |
5593424 | Northrup III | Jan 1997 | A |
RE35459 | Junkman | Feb 1997 | E |
5601576 | Garrison | Feb 1997 | A |
5601581 | Fogarty et al. | Feb 1997 | A |
5609598 | Laufer et al. | Mar 1997 | A |
5613937 | Garrison et al. | Mar 1997 | A |
5618270 | Orejola | Apr 1997 | A |
5643292 | Hart | Jul 1997 | A |
5653744 | Khouri | Aug 1997 | A |
5655548 | Nelson | Aug 1997 | A |
5662124 | Wilk | Sep 1997 | A |
5662711 | Douglas | Sep 1997 | A |
5676670 | Kim | Oct 1997 | A |
5682906 | Sterman et al. | Nov 1997 | A |
5685857 | Negus et al. | Nov 1997 | A |
5693083 | Baker et al. | Dec 1997 | A |
5702368 | Stevens et al. | Dec 1997 | A |
5702412 | Popov et al. | Dec 1997 | A |
5715832 | Koblish et al. | Feb 1998 | A |
5716367 | Koike et al. | Feb 1998 | A |
5718725 | Sterman et al. | Feb 1998 | A |
5722426 | Kolff | Mar 1998 | A |
5725537 | Green et al. | Mar 1998 | A |
5727569 | Benetti et al. | Mar 1998 | A |
5728151 | Garrison et al. | Mar 1998 | A |
5735290 | Sterman et al. | Apr 1998 | A |
5738649 | Macoviak | Apr 1998 | A |
5738652 | Boyd et al. | Apr 1998 | A |
5749892 | Vierra et al. | May 1998 | A |
5752526 | Cosgrove | May 1998 | A |
5755682 | Knudson et al. | May 1998 | A |
5755687 | Donlon | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5758663 | Wilk et al. | Jun 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5769812 | Stevens et al. | Jun 1998 | A |
5792094 | Stevens et al. | Aug 1998 | A |
5795325 | Valley et al. | Aug 1998 | A |
5797920 | Kim | Aug 1998 | A |
5797933 | Snow et al. | Aug 1998 | A |
5799661 | Boyd et al. | Sep 1998 | A |
5800450 | Lary et al. | Sep 1998 | A |
5800552 | Forte | Sep 1998 | A |
5836311 | Borst et al. | Nov 1998 | A |
5849036 | Zarate | Dec 1998 | A |
5855210 | Sterman et al. | Jan 1999 | A |
5855614 | Stevens et al. | Jan 1999 | A |
5868770 | Rygaard | Feb 1999 | A |
5893369 | LeMole | Apr 1999 | A |
5895404 | Ruiz | Apr 1999 | A |
5904147 | Conlan et al. | May 1999 | A |
5904690 | Middleman et al. | May 1999 | A |
5921979 | Kovac et al. | Jul 1999 | A |
5928181 | Coleman et al. | Jul 1999 | A |
5944019 | Knudson et al. | Aug 1999 | A |
5947125 | Benetti | Sep 1999 | A |
5947919 | Krueger et al. | Sep 1999 | A |
5976178 | Goldsteen et al. | Nov 1999 | A |
6026814 | LaFontaine et al. | Feb 2000 | A |
6035856 | LaFontaine et al. | Mar 2000 | A |
6155264 | Ressemann et al. | Dec 2000 | A |
6253769 | LaFontaine et al. | Jul 2001 | B1 |
6390098 | LaFontaine et al. | May 2002 | B1 |
6575168 | LaFontaine et al. | Jun 2003 | B1 |
Number | Date | Country |
---|---|---|
0 769 272 | Jul 1997 | EP |
97281410 | Jul 1997 | JP |
1600708 | Dec 1995 | RU |
308752 | Jul 1971 | SU |
388738 | Sep 1971 | SU |
891076 | Dec 1981 | SU |
1822750 | Jul 1982 | SU |
WO 9508364 | Mar 1995 | WO |
WO 9510218 | Apr 1995 | WO |
WO 9515192 | Jun 1995 | WO |
WO 9516476 | Jun 1995 | WO |
WO 9610375 | Apr 1996 | WO |
WO 9617644 | Jun 1996 | WO |
WO 9625886 | Aug 1996 | WO |
WO 9630072 | Oct 1996 | WO |
WO 9630073 | Oct 1996 | WO |
WO 9632882 | Oct 1996 | WO |
WO 9712555 | Apr 1997 | WO |
WO 9713463 | Apr 1997 | WO |
WO 9713468 | Apr 1997 | WO |
WO 9713471 | Apr 1997 | WO |
WO 9726939 | Jul 1997 | WO |
WO 9737984 | Oct 1997 | WO |
WO 9740751 | Nov 1997 | WO |
WO 9806356 | Feb 1998 | WO |
WO 9807399 | Feb 1998 | WO |
WO 9810714 | Mar 1998 | WO |
WO 9816161 | Apr 1998 | WO |
WO 9816174 | Apr 1998 | WO |
WO 9817182 | Apr 1998 | WO |
WO 9817187 | Apr 1998 | WO |
WO 9815237 | May 1998 | WO |
WO 9819607 | May 1998 | WO |
WO 9819634 | May 1998 | WO |
WO 9819636 | May 1998 | WO |
WO 9831302 | Jul 1998 | WO |
WO 9832380 | Jul 1998 | WO |
WO 9835626 | Aug 1998 | WO |
WO 9837814 | Sep 1998 | WO |
WO 9851223 | Nov 1998 | WO |
WO 9852475 | Nov 1998 | WO |
WO 9857590 | Dec 1998 | WO |
WO 9857591 | Dec 1998 | WO |
WO 9857592 | Dec 1998 | WO |
WO 9904836 | Feb 1999 | WO |
WO 9904845 | Feb 1999 | WO |
WO 9917683 | Apr 1999 | WO |
WO 9918887 | Apr 1999 | WO |
WO 9935975 | Jul 1999 | WO |
WO 9935977 | Jul 1999 | WO |
WO 9935978 | Jul 1999 | WO |
WO 9935979 | Jul 1999 | WO |
WO 9935980 | Jul 1999 | WO |
WO 9936000 | Jul 1999 | WO |
WO 9936001 | Jul 1999 | WO |
WO 9938459 | Aug 1999 | WO |
WO 9940853 | Aug 1999 | WO |
WO 9940868 | Aug 1999 | WO |
Number | Date | Country | |
---|---|---|---|
20030195457 A1 | Oct 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 08813038 | Mar 1997 | US |
Child | 09391112 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09759996 | Jan 2001 | US |
Child | 10436863 | US | |
Parent | 09391112 | Sep 1999 | US |
Child | 09759996 | US |